Nonpeptide αvβ3 Antagonists. 1. Transformation of a Potent, Integrin-Selective αIIbβ3 Antagonist into a Potent αvβ3 Antagonist
摘要:
Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7,8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.
Synthesis of Arrays Using Low Molecular Weight MPEG-Assisted Mitsunobu Reaction
摘要:
Triphenylphosphine tagged with a short poly(ethyleneglycol)-omega-monomethyl ether chain (light MPEG, 10-16 ethylenoxy units, (TPP)-T-M-G2) and an MPEG-tagged version of diethyl azodicarboxylate ((M)DEAD) have been used to prepare a 20 member library of esters, ethers, and sulfonamides, with cLogP's in the range of 1.4-5.7 on a 0.1 mmol scale. Removal of MPEG-tagged side products was achieved by MPEG-assisted solid-phase extraction (MSPE) on prepacked silica columns to give the products in good yield and high purity.
Novel fibrinogen receptor antagonists of the formula: X--Y--Z--Aryl--A--B are provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.
[EN] FIBRINOGEN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS DU FIBRINOGENE
申请人:——
公开号:WO1994012181A1
公开(公告)日:1994-06-09
[EN] Novel fibrinogen receptor antagonists of the formula: X-Y-Z-Aryl-A-B are provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation. [FR] L'invention concerne des nouveaux antagonistes des récepteurs du fibrinogène représentés par la formule: X-Y-Z-Aryl-A-B Les composés selon l'invention agissent en tant qu'antagonistes des récepteurs du fibrinogène, inhibent l'agrégation plaquettaire et sont utilisés pour moduler la formation de thrombus.